Pientzehuang

Pientzehuang is a Chinese traditional medicine brand identified primarily with the traditional Chinese medicine preparation known as 片仔癀. The name is associated with a proprietary traditional formulation and with the broader commercial identity built around that product. It belongs to the consumer health and traditional Chinese medicine segment rather than to mainstream prescription pharmaceuticals or ordinary food and beverage brands. The brand’s significance comes from the cultural and commercial value attached to its formula, long-standing traditional-medicine positioning, and recognizable Chinese name. Pientzehuang is commonly presented as a traditional Chinese patent medicine, meaning that it is manufactured in a standardized finished form rather than compounded individually for each patient. The product and brand are associated with traditional uses in areas such as inflammation-related discomfort and recovery, although product indications, permitted claims, ingredients, and directions should be verified against the applicable regulatory labeling and official documentation. The brand is also linked in public business references with the Pientzehuang pharmaceutical enterprise based in Zhangzhou, Fujian, but the supplied materials do not establish a complete corporate ownership history, founding date, executive roster, or current legal relationship between the brand and a specific parent company. Those corporate details are therefore left unfilled. Similarly, no reliable financial information, stock ticker, campaign archive, or documented controversy was provided for this entry. Commercially, Pientzehuang is best understood as a focused traditional-medicine brand rather than a diversified consumer conglomerate. Its central offering is the namesake preparation, while related categories may include traditional medicine products, topical or personal-care products, and other health-oriented goods sold under associated corporate or brand structures. The precise product portfolio, international distribution footprint, and current sales channels require verification from official product catalogs and regulatory records. The brand’s supplied website is retained as the submitted reference URL, but the available reference material describes that domain as being offered for sale and does not provide verified brand information. It should not therefore be treated as confirmation of current official ownership or as evidence for corporate, product, or financial claims. This dossier records Pientzehuang as an active Chinese traditional medicine brand, with several historical and corporate fields requiring further source-based review.

Pientzehuang’s history is rooted in the Chinese traditional medicine tradition and in the commercial use of the name 片仔癀 for a standardized traditional preparation. The supplied reference material identifies the subject broadly as a traditional Chinese medicine brand but does not provide a reliable chronology, documentary account of its origin, verified founder, or a complete record of corporate development. As a result, a detailed historical narrative cannot responsibly be constructed from the available evidence. In brand terms, Pientzehuang is distinguished from a general category label by the prominence of its specific namesake formulation. The brand identity is built around the perceived heritage and proprietary character of that preparation, while the surrounding business identity may encompass manufacturing, distribution, and related health or personal-care products. The exact boundaries between the core product trademark, the commercial brand, and the pharmaceutical company associated with the name require confirmation through trademark registrations, regulatory product records, and official corporate disclosures. The available material does not substantiate particular founding dates, historical production sites, formulation changes, export milestones, advertising campaigns, acquisitions, or leadership transitions. It also does not document verified sales figures, valuation data, or public-market information for the brand itself. Such omissions are intentional: corporate facts about a related pharmaceutical company should not be automatically attributed to the product brand without a reliable source. The submitted website cannot currently serve as a dependable historical source. The reference describing it indicates that the domain is available for sale, rather than presenting a verified corporate or product archive. Further research should prioritize official regulatory filings, recognized Chinese medicine and pharmaceutical databases, trademark records, archived company publications, and independently verifiable corporate disclosures. Until those sources are available, Pientzehuang should be documented as an active Chinese traditional medicine brand with a well-defined namesake product but an incompletely sourced public history.

• 1992

  China promulgates the Regulations on Protection of Traditional Chinese Medicines, under which Pientzehuang becomes one of only four national first-class protected varieties.

• Pientzehuang retains national first-class protection status across more than three decades of the regulation.

A heritage-oriented Chinese traditional medicine and consumer health brand centered on a proprietary namesake preparation.

• Traditional Chinese patent medicine

  Pientzehuang

  The namesake traditional Chinese medicine preparation and the core offering associated with the Pientzehuang brand. It is positioned within the traditional Chinese patent medicine category, in which a prepared formulation is manufactured and packaged for consumer or patient use. Specific ingredients, approved indications, dosage instructions, manufacturing history, and regulatory status are not established by the supplied sources and should be checked against current official labeling.

• 2023

  Former chairman Liu Jianshun expelled from the Communist Party and referred to procuratorate

  In August 2023, the Zhangzhou Municipal Commission for Discipline Inspection and Supervisory Commission announced that Liu Jianshun, former chairman of Pien Tze Huang Pharmaceutical, was expelled from the Communist Party and stripped of his benefits, and that suspected crimes including bribery were referred to the procuratorate for review and prosecution. This source concerns the disciplinary action and referral stage.

  Source

• 2021

  Price speculation, scalper hoarding and 'exaggerated efficacy' claims reported, case opened

  Pien Tze Huang raised prices about 20 times over 20 years; under purchase limits, scalpers hoarded and resold it, driving prices as high as about 1,600 yuan per pill. In the first Pien Tze Huang reselling case, the defendant was sentenced for illegal business operations; in 2023, company executives were investigated; in 2026, consumers reported stores for off-label claims such as "curing cancer," and the Beijing Dongcheng District Market Supervision Administration opened an investigation, while a separate "exaggerated efficacy" lawsuit remains pending. The investigation is ongoing.

  Source

Read more

• 2026.10.13

  Pien Tze Huang chairman and legal representative Lin Zhihui resigns[10]片仔癀董事长、法定代表人林志辉辞职stcn.com

  Pien Tze Huang (600436) announced on the evening of October 13 that its chairman and legal representative Lin Zhihui, citing work adjustment, submitted a resignation report to the board, stepping down as chairman and also resigning as director and member of relevant special committees; after leaving he will hold no position at the company or its subsidiaries. The company said the resignation will not affect normal production and operations and that it will complete the selection of a new chairman as soon as possible per legal procedures.

• Unconfirmed

  Reported2021.12.12

  Pien Tze Huang appoints new chairman[11]片仔癀聘任新董事长finance.sina.com.cn

  Pien Tze Huang said its board agreed to appoint Lin Weiqi as chairman.

• 2021.04.07

  Reported2021.04.07

  Pien Tze Huang appoints Pan Jie as chairperson[12]片仔癀聘任潘杰为董事长finance.sina.com.cn

  Pien Tze Huang's board agreed to appoint Pan Jie as chairperson on April 7, 2021; the article also reports that Liu Jianshun resigned from the chairperson role.

• 2020.07.24

  Reported2020.07.24

  Pien Tze Huang acquires 51% of Longhui Pharmaceutical[13]片仔癀取得龙晖药业51%股权finance.sina.com.cn

  Pien Tze Huang announced that it invested approximately RMB 44.4759 million of its own funds in Longhui Pharmaceutical and obtained a 51% equity stake.

Read more

1. 1Submitted brand website referencezpc.com.cn
2. 2片仔癀 - 维基百科zh.wikipedia.org
3. 3关于域名｜zpc.com.cnzpc.com.cn
4. 4zpc.com.cn域名含义与品牌价值｜ZPC中国域名zpc.com.cn
5. 5Former chairman Liu Jianshun expelled from the Communist Party and referred to procuratoratenbd.com.cn
6. 6Former chairman Liu Jianshun expelled from the Communist Party and referred to procuratoratenews.cnr.cn
7. 7Price speculation, scalper hoarding and 'exaggerated efficacy' claims reported, case openedthepaper.cn
8. 8Price speculation, scalper hoarding and 'exaggerated efficacy' claims reported, case openedthepaper.cn
9. 9Price speculation, scalper hoarding and 'exaggerated efficacy' claims reported, case openednews.qq.com
10. 10片仔癀董事长、法定代表人林志辉辞职stcn.com
11. 11片仔癀聘任新董事长finance.sina.com.cn
12. 12片仔癀聘任潘杰为董事长finance.sina.com.cn
13. 13片仔癀取得龙晖药业51%股权finance.sina.com.cn
14. 14扩产品线 片仔癀收购龙晖药业finance.sina.com.cn
15. 15片仔癀董事长辞职finance.sina.com.cn
16. 16片仔癀董事长辞职stcn.com
17. 17片仔癀董事长林志辉辞职，上月刚敲定新任总经理，营收、净利连续承压finance.sina.com.cn
18. 18片仔癀董事长林志辉辞职，上月刚敲定新任总经理，营收、净利连续承压163.com